Assertio Therapeutics Inc (ASRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has a cash flow conversion efficiency ratio of -0.319x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.97 Million) by net assets ($93.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Assertio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ASRT liabilities breakdown for a breakdown of total debt and financial obligations.
Assertio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assertio Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mitrabara Adiperdana PT
JK:MBAP
|
-0.004x |
|
Distribuidora de Gas Cuyana SA
BA:DGCU2
|
0.087x |
|
Eastern Water Resources Development and Management Public Company Limited
F:7ES1
|
0.033x |
|
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
|
-0.151x |
|
Shanghai Diesel Engine Co Ltd B
SHG:900920
|
0.101x |
|
SYN prop e tech S.A.
SA:SYNE3
|
0.017x |
|
Finder Energy Holdings Ltd
AU:FDR
|
-0.630x |
|
RTX A/S
CO:RTX
|
0.041x |
Annual Cash Flow Conversion Efficiency for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see ASRT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.95 Million | $-28.18 Million | -0.300x | -237.53% |
| 2024-12-31 | $121.08 Million | $26.41 Million | 0.218x | -39.32% |
| 2023-12-31 | $138.00 Million | $49.60 Million | 0.359x | +3.23% |
| 2022-12-31 | $225.72 Million | $78.60 Million | 0.348x | +545.68% |
| 2021-12-31 | $102.41 Million | $5.52 Million | 0.054x | +104.57% |
| 2020-12-31 | $55.51 Million | $-65.57 Million | -1.181x | -175.67% |
| 2019-12-31 | $57.96 Million | $90.47 Million | 1.561x | +374.44% |
| 2018-12-31 | $220.34 Million | $72.50 Million | 0.329x | -10.28% |
| 2017-12-31 | $169.51 Million | $62.17 Million | 0.367x | +40.42% |
| 2016-12-31 | $250.79 Million | $65.50 Million | 0.261x | -42.81% |
| 2015-12-31 | $315.06 Million | $143.89 Million | 0.457x | +397.67% |
| 2014-12-31 | $364.45 Million | $-55.92 Million | -0.153x | -316.15% |
| 2013-12-31 | $137.42 Million | $9.75 Million | 0.071x | +119.23% |
| 2012-12-31 | $83.94 Million | $-30.98 Million | -0.369x | -167.82% |
| 2011-12-31 | $105.92 Million | $57.65 Million | 0.544x | +628.20% |
| 2010-12-31 | $23.11 Million | $-2.38 Million | -0.103x | -188.17% |
| 2009-12-31 | $15.73 Million | $1.84 Million | 0.117x | +15.63% |
| 2008-12-31 | $33.15 Million | $3.35 Million | 0.101x | -68.62% |
| 2007-12-31 | $45.52 Million | $14.66 Million | 0.322x | -68.27% |
| 2006-12-31 | $-27.29 Million | $-27.70 Million | 1.015x | -76.18% |
| 2005-12-31 | $6.76 Million | $28.82 Million | 4.262x | +253.93% |
| 2004-12-31 | $8.40 Million | $-23.27 Million | -2.769x | -188.82% |
| 2003-12-31 | $34.58 Million | $-33.15 Million | -0.959x | -238.57% |
| 2002-12-31 | $-6.41 Million | $-4.44 Million | 0.692x | -91.76% |
| 2001-12-31 | $-1.48 Million | $-12.40 Million | 8.393x | +678.64% |
| 2000-12-31 | $4.59 Million | $-6.65 Million | -1.451x | -238.96% |
| 1999-12-31 | $9.22 Million | $-3.94 Million | -0.428x | -57.48% |
| 1998-12-31 | $9.20 Million | $-2.50 Million | -0.272x | -1.28% |
| 1997-12-31 | $4.10 Million | $-1.10 Million | -0.268x | -126.83% |
| 1996-12-31 | $-400.00K | $-400.00K | 1.000x | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more